Intrathecal Additives for Spinal Anaesthesia in Elective Caesarean Sections
Primary Purpose
Pain, Postoperative
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
intrathecal Magnesium
intrathecal dexamthasone
intrathecal dexmedetomidine
Sponsored by
About this trial
This is an interventional other trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists classII-III adult female patient (age :18 -40 years old )
- Elective cesarean section under spinal anaesthesia
- Gestational age > 37 weeks
- BMI less than 30 kg/m2
Exclusion Criteria:
- Patient refusal
- unable to give consent
- age < 18 or > 40
- BMI more than 30 kg/m2
- known allergy to the study medication
- coagulopathies or on anticoagulant medications
- diabetic neuropathy
- patients with psychiatric disorders
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
magnesium intrathecal
dexamethasone intrathecal
dexmedetomidine intrathecal
Arm Description
Outcomes
Primary Outcome Measures
analgesic effect
duration of sensory block
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04747171
Brief Title
Intrathecal Additives for Spinal Anaesthesia in Elective Caesarean Sections
Official Title
A Comparative Study of Postoperative Analgesia of Different Intrathecal Additives for Spinal Anaesthesia in Elective Caesarean Sections
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 2021 (Anticipated)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
July 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Benha University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
we designed this randomized, single -blind, prospective clinical study to test postoperative analgesia of three intrathecal additives in elective caesarean sections which are magnesium, dexamethasone and dexmedetomidine.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
105 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
magnesium intrathecal
Arm Type
Active Comparator
Arm Title
dexamethasone intrathecal
Arm Type
Active Comparator
Arm Title
dexmedetomidine intrathecal
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
intrathecal Magnesium
Intervention Description
intrathecal adjuvants to bupivacaine
Intervention Type
Drug
Intervention Name(s)
intrathecal dexamthasone
Intervention Description
intrathecal adjuvants to bupivacaine
Intervention Type
Drug
Intervention Name(s)
intrathecal dexmedetomidine
Intervention Description
intrathecal adjuvants to bupivacaine
Primary Outcome Measure Information:
Title
analgesic effect
Description
duration of sensory block
Time Frame
Up to 24 hours after surgery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists classII-III adult female patient (age :18 -40 years old )
Elective cesarean section under spinal anaesthesia
Gestational age > 37 weeks
BMI less than 30 kg/m2
Exclusion Criteria:
Patient refusal
unable to give consent
age < 18 or > 40
BMI more than 30 kg/m2
known allergy to the study medication
coagulopathies or on anticoagulant medications
diabetic neuropathy
patients with psychiatric disorders
12. IPD Sharing Statement
Learn more about this trial
Intrathecal Additives for Spinal Anaesthesia in Elective Caesarean Sections
We'll reach out to this number within 24 hrs